Alvotech Targets Chinese Biosimilars With Yangtze River Deal

Exclusive Partnership Covers Eight Biosimilar Candidates In China

Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.

Business_China
The deal offers access to China for Alvotech’s biosimilars portfolio • Source: Shutterstock

Yangtze River Pharmaceutical will market eight Alvotech biosimilars in China, under the terms of an exclusive deal that has just been agreed with the Alvogen sister company. The agreement involves the Alvotech & CCHT Biopharmaceutical joint venture between Alvotech and Changchun High & New Technology Industries – founded in March 2019 – and provides for biosimilar candidates to be manufactured in a new Chinese facility being constructed in Changchun.

“Through this partnership, a powerhouse has been created in one of the world’s largest biologics markets, designed to improve patient...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

Nexus Faces Five Year Wait On Injectable Minocycline

Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

test

uygukgigo

 
• By 

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.